Company / Revenue
Alaunos Therapeutics, Inc. Revenue History
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$10.0K
FY2025
5-year range
$0 / $2.9M
FY2021-FY2025
Trend
+100.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has fluctuated over the past 9 years, ranging from $0 in FY2021 to $16M in FY2019.
Based on SEC 10-K filings.
$10,000 in FY2025 with a 5-year CAGR of -41.5%.
Declined from $3M to $10,000 over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -70.7%
- 5-Year CAGR
- -41.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -41.5%, indicating a declining trend.
- In FY2025, revenue increased 100.0% year-over-year.
- Peak revenue was recorded in FY2019.
- Lowest revenue in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.79 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.0K | +100.0% |
| FY2024 | $5.0K | -99.8% |
| FY2023 | $2.9M | +634.2% |
| FY2022 | $398.0K | - |
| FY2021 | $0 | -100.0% |
| FY2020 | $146.0K | -99.1% |
| FY2019 | $15.9M | +0.0% |
| FY2018 | $15.9M | - |
| FY2013 | - | - |
| FY2012 | $667.0K | +0.0% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026